Therapies
Read more about Low Dose Naltrexone
About Us
Discover Immune Therapeutics
Find a Doctor
Locate LDN prescribing doctors near you

LDN (low dose naltrexone)

Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator.

MENK

OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.

Find A Doctor
doctor_locator
LDN App

LDN Health Tracker App

0 23 January 2015

Orlando, Florida and Dublin, Ireland, January 23, 2015 – Immune Therapeutics, Inc. today announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.

KRS Global is a 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets in various strengths for individual patients in response to a prescription from a licensed physician.

Posted in Press Releases by admin
0 21 January 2015

ORLANDO, Fla. and DUBLIN, Jan. 21, 2015 /PRNewswire/ — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 Annual Meeting of Shareholders, joined the Board on January 13, 2015.

Ms. Noreen Griffin, Chief Executive Officer of Immune Therapeutics, stated, “We are very excited to bring on these new board members as this allows us to begin to make the changes we promised at our annual meeting. We believe these people bring the changes necessary to advance the company to the next level.”

Posted in Press Releases by admin
0 14 January 2015

ORLANDO, Fla. and DUBLIN, Ireland, Jan. 14, 2015 /PRNewswire/ — Immune Therapeutics Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced the appointment of Seth Elliot as President and Chief Operating Officer.

As part of the changes in management, Dr. Eugene Youkilis and Christopher Pearce have stepped down as officers of Immune Therapeutics but will continue to serve as members of the board of directors. Christopher Pearce will also continue to serve as a director of Airmed Biopharma Limited and Sr. Vice President of TNI BioTech International, Ltd.

Posted in Press Releases by admin
Load More